MILPITAS, Calif. -
May 11, 2018 -
PRLog -- Phosphoglycerate Dehydrogenase (PHGDH: EC 1.1.1.95) is the first enzyme that participates in the L-serine synthesis pathway. PHGDH catalyzes the reversible reaction that converts 3-phosphoglycerate into 3-phosphohydroxyglycerate and the NADH-dependent reduction of α-ketoglutarate into D-2-hydroxyglutarate (D-2HG). In humans, PHGDH deficiency causes severe health problems including congenital microcephaly, psychomotor retardation, and intractable seizure. Recent studies have shown increased PHGDH activity in a wide variety of cancers, particularly in breast and melanoma tumors. Therefore, the measurement of PHGDH activity has become of great importance in searching potential therapeutic agents against cancer. BioVision's Phosphoglycerate Dehydrogenase Assay kit provides a quick and easy method for monitoring PHGDH activity in a variety of samples. In this kit, Phosphoglycerate Dehydrogenase converts 3-phosphoglycerate and NAD into 3-phosphohydroxyglerate and NADH respectively. The oxidation of NADH reduces a probe generating a strong, stable absorbance signal (OD: 450 nm). The assay is simple, sensitive, high–throughput adaptable and can detect Phosphoglycerate Dehydrogenase activity less than 0.1 mU per sample.
Figure: Relative PHGDH Activity using
K569-100 was calculated in lysates prepared from HEK cells (4.5 µg) and HeLa cells (7.8 µg). Assays were performed following kit protocol.
For detailed information on this product visit:
https://www.biovision.com/phosphoglycerate-dehydrogenase-...
